Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3454738 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
The vIGA-AD measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification
| Arm | Type | Description |
|---|---|---|
| LY3454738 - Part A | EXPERIMENTAL | Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants |
| Placebo - Part A | PLACEBO_COMPARATOR | Placebo administered IV to healthy participants |
| LY3454738 - Part B | EXPERIMENTAL | LY3454738 administered IV to healthy participants |
| Placebo - Part B | PLACEBO_COMPARATOR | Placebo administered IV to healthy participants |
| LY3454738 - Part C | EXPERIMENTAL | LY3454738 administered IV to participants with atopic dermatitis (AD) |
| Placebo - Part C | PLACEBO_COMPARATOR | Placebo administered IV to participants with AD |
| Name | Type | Description |
|---|---|---|
| LY3454738 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * All: Must have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive, for Parts A and B, and 18.0 to 45.0 kg/m², inclusive, for Part C and a minimum body weight of 50 kilograms * For PART A and B only, regarding the inclusion of healthy Japanese parti...
LY3454738 is an investigational small molecule being studied for atopic dermatitis, a form of eczema. It is being developed by Eli Lilly and Company as a potential treatment in dermatology. The compound has been evaluated in a Phase 1 clinical trial that included both healthy participants and participants with atopic dermatitis.
LY3454738 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company sponsored the Phase 1 study of the compound in healthy volunteers and participants with atopic dermatitis.
LY3454738 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
LY3454738 has been studied in a single Phase 1 trial, NCT03750643, titled A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis. The trial was completed and enrolled 128 participants across the United States and Puerto Rico.
The Phase 1 trial NCT03750643 was a randomized, double-blind, placebo-controlled study. It enrolled 128 participants, including healthy volunteers and participants with atopic dermatitis, aged 18 years and older of all sexes. The study was conducted in the United States and Puerto Rico.